Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 9, 2016, Pages 1627-1635

  Allewelt, Heather ^a   El Khorazaty, Jill ^b   Mendizabal, Adam ^b   Taskindoust, Mahsa ^a   Martin, Paul L ^a   Prasad, Vinod ^a   Page, Kristin ^a   Sanders, Jean ^c   Kurtzberg, Joanne ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EMMES CORPORATION   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Busulfan; Late effects; Myeloablative conditioning; Umbilical cord blood transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; STEROID; THYMOCYTE ANTIBODY; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; COGNITIVE DEFECT; COHORT ANALYSIS; CORD BLOOD STEM CELL TRANSPLANTATION; ENTERAL DRUG ADMINISTRATION; FEMALE; FOLLOW UP; GLOBOID CELL LEUKODYSTROPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HUMAN; HURLER SYNDROME; IMMUNE DEFICIENCY; INCIDENCE; LEUKEMIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOPOLYSACCHARIDOSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; PUBERTY; RETROSPECTIVE STUDY; SHORT STATURE; TOOTH DISEASE; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION; ADVERSE DRUG REACTION; CHEMICALLY INDUCED DISORDER; INFANT; MORTALITY; PRESCHOOL CHILD; PROCEDURES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

BUSULFAN; CHEMICALLY-INDUCED DISORDERS; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOLLOW-UP STUDIES; HUMANS; INFANT; LONG TERM ADVERSE EFFECTS; MYELOABLATIVE AGONISTS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

EID: 84978920140     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.05.024     Document Type: Article

References (32)

1. 1 Kurtzberg, J., Laughlin, M., Graham, M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335 (1996), 157–166.
2. 2 Pulsipher, M.A., Skinner, R., McDonald, G.B., et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant 18 (2012), 334–347.
3. 3 Cohen, A., Rovelli, A., Van-Lint, M.T., et al. Final height of patients who underwent bone marrow transplantation during childhood. Arch Dis Childhood 74 (1996), 437–440.
4. 4 Dahllof, G., Hingorani, S.R., Sanders, J.E., Late effects following hematopoietic cell transplantation for children. Biol Blood Marrow Transplant 14:1 Suppl 1 (2008), 88–93.
5. 5 Dvorak, C.C., Gracia, C.R., Sanders, J.E., et al. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks. Biol Blood Marrow Transplant 17 (2011), 1725–1738.
6. 6 Faraci, M., Barra, S., Cohen, A., et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 63 (2005), 1568–1575.
7. 7 Giorgiani, G., Bozzola, M., Locatelli, F., et al. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 86 (1995), 825–831.
8. 8 Nieder, M.L., McDonald, G.B., Kida, A., et al. National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. Biol Blood Marrow Transplant 17 (2011), 1573–1584.
9. 9 Parsons, S.K., Phipps, S., Sung, L., et al. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: health-related quality of life, functional, and neurocognitive outcomes. Biol Blood Marrow Transplant 18 (2012), 162–171.
10. 10 Phipps, S., Rai, S.N., Leung, W.H., et al. Cognitive and academic consequences of stem-cell transplantation in children. J Clin Oncol 26 (2008), 2027–2033.
11. 11 Sanders, J., Sullivan, K., Witherspoon, R., et al. Long term effects and quality of life in children and adults after marrow transplantation. Bone Marrow Transplant 4:Suppl 4 (1989), 27–29.
12. 12 Sanders, J.E., Growth and development after hematopoietic cell transplant in children. Bone Marrow Transplant 41 (2008), 223–227.
13. 13 Sanders, J.E., Guthrie, K.A., Hoffmeister, P.A., et al. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood 105 (2005), 1348–1354.
14. 14 Sanders, J.E., Hoffmeister, P.A., Woolfrey, A.E., et al. Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience. Blood 113 (2009), 306–308.
15. 15 Sanders, J.E., Woolfrey, A.E., Carpenter, P.A., et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood 118 (2011), 1421–1428.
16. 16 Wilhelmsson, M., Vatanen, A., Borgstrom, B., et al. Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT—two decades of longitudinal follow-up. Bone Marrow Transplant 50 (2015), 850–857.
17. 17 Willard, V.W., Leung, W., Huang, Q., et al. Cognitive outcome after pediatric stem-cell transplantation: impact of age and total-body irradiation. J Clin Oncol 32 (2014), 3982–3988.
18. 18 Dahllof, G., Oral and dental late effects after pediatric stem cell transplantation. Biol Blood Marrow Transplant 14:1 Suppl 1 (2008), 81–83.
19. 19 Sanders, J.E., Im, H.J., Hoffmeister, P.A., et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 105 (2005), 3749–3756.
20. 20 Prasad, V.K., Mendizabal, A., Parikh, S.H., et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 112 (2008), 2979–2989.
21. 21 Beam, D., Poe, M.D., Provenzale, J.M., et al. Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy. Biol Blood Marrow Transplant 13 (2007), 665–674.
22. 22 Martin, H.R., Poe, M.D., Provenzale, J.M., et al. Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. Biol Blood Marrow Transplant 19 (2013), 616–624.
23. 23 Kurtzberg, J., Cairo, M.S., Fraser, J.K., et al. Results of the Cord Blood Transplantation (COBLT) study unrelated donor banking program. Transfusion 45 (2005), 842–855.
24. 24 Kurtzberg, J., Prasad, V.K., Carter, S.L., et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 112 (2008), 4318–4327.
25. 25 Martin, P.L., Carter, S.L., Kernan, N.A., et al. Results of the Cord Blood Transplantation Study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant 12 (2006), 184–194.
26. 26 Shulman, H.M., Sullivan, K.M., Weiden, P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980), 204–217.
27. 27 Rowlings, P.A., Przepiorka, D., Klein, J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 97 (1997), 855–864.
28. 28 National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Rev ed, 2009, U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD.
29. 29 Copelan, E., Casper, J.T., Carter, S.L., et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 13 (2007), 1469–1476.
30. 30 Bunin, N., Small, T., Szabolcs, P., et al. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors. Biol Blood Marrow Transplant 18 (2012), 6–15.
31. 31 Hoffmeister, P.A., Madtes, D.K., Storer, B.E., Sanders, J.E., Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation. Pediatr Blood Cancer 47 (2006), 594–606.
32. 32 Ando, M., Ohashi, K., Akiyama, H., et al. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Nephrol Dialys Transplant 25 (2010), 278–282.